This technology appraisal was originally included in scope for ID858, however as NICE is unable to release any recommendations on 177Lu-dotatate until it has a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, this has been separated. The recommendations for everolimus and sunitinib can be found on the NICE website.